YUM! Brands $1.05 billion senior notes offering
Davis Polk advised the representative of the underwriters in connection with an SEC-registered offering by YUM! Brands, Inc. of $1.05 billion aggregate principal amount of 3.625%…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…
Toronto-Dominion Bank $2.25 billion notes offering
Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.25 billion aggregate principal amount of its 0.450% senior notes due 2023 and (ii) $1 billion…
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…
TFI International $218.8 million follow-on offering
Davis Polk advised the joint lead book-running managers in connection with the $218.8 million public offering of 5,060,000 common shares of TFI International, Inc., which included 660…
Warner Music Group $550 million notes offering
Davis Polk advised the joint book-running managers and the initial purchasers in a Rule 144A/Regulation S offering of $550 million principal amount of 3.000% senior secured notes due…
Kinsale Capital Group $59 million follow-on offering
Davis Polk advised the sole book-running manager and representative of the underwriters in connection with the $59 million follow-on offering of 310,500 shares of common stock of Kinsale…
BioXcel Therapeutics $200 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000,000 shares of its common stock. The common stock is listed on the…
Freeport-McMoRan $1.5 billion notes offering
Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.5 billion of senior notes. The offering consisted of $650 million of 4.375% senior…